| ORGANON + CO. DL -,01 |
| USA |
| Gesundheit |
| US68622V1061 / A3CPKP |
| 7XP (Frankfurt) / OGN (NYSE) |
| FRA:7XP, ETR:7XP, 7XP:GR, NYSE:OGN |
| S&P500 |
| https://www.organon.com/ |
|
Organon & Co. is a global healthcare company that focuses primarily on the discovery, development, manufacture, and commercialization of therapeutic solutions. Its primary function is to address the needs of women, with a significant emphasis on fami..
>Volltext.. |
| 1282.94 Mio. EUR |
| 8224.49 Mio. EUR |
| 5374.54 Mio. EUR |
| 1381.68 Mio. EUR |
| 161.69 Mio. EUR |
| 0.62 EUR |
| 7608.74 Mio. EUR |
| 496.3 Mio. EUR |
| 605.24 Mio. EUR |
| 0.24 |
| -14.43% |
| -80.92% |
| 0.07 EUR |
| 1.37% |
| 1.38% |
| 23.02.26 - 0.016962€ 20.11.25 - 0.017355999€ >weitere anzeigen... |
| - |
| ORGANON |
| 03.04.26 |
|